Holen Sie sich die Stockscreener-App
2.80
1.75%
-0.05
Serina Therapeutics Inc Aktie (SER) Neueste Nachrichten
Serina Therapeutics Q2 Results: EPS Misses Estimate, Sales Flat - scanx.trade
Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates - GlobeNewswire
Serina Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Serina Therapeutics Inc (SER) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Serina Therapeutics Inc (SER) Stock News Today - TradingKey
Serina Therapeutics Inc. (SER) Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues to Invest in PipelineReturn On Equity - dars.gov.et
Serina Therapeutics Inc (SER) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Serina Therapeutics Inc (SER) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Serina Therapeutics Inc (SER) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
SER|Serina Therapeutics Inc|Price:2.030|Chg%:-0.040 - TradingKey
Serina Therapeutics Market Sentiment - Benzinga España
Serina Therapeutics Inc (SER) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Serina Therapeutics Inc (SER) Balance Sheet - TradingKey
Serina Therapeutics, Inc. Revenue Breakdown – AMEX:SER - TradingView
Serina Therapeutics, Inc. Revenue Breakdown – TRADEGATE:2BO - TradingView
TradingKey - TradingKey
Serina Therapeutics Inc (SER) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SER|Serina Therapeutics Inc|Price:1.990|Chg%:-0.080 - TradingKey
Serina Therapeutics to present at BTIG Virtual Biotechnology Conference July 28-29, 2026 - Pluang
Serina Therapeutics, Inc. Amended CEO Employment Agreement and SEC Filing Details – July 2026 - Minichart
Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference - The Manila Times
Serina Sets July 29 Virtual Investor Meetings at BTIG Event - Stock Titan
Form 4 Serina Therapeutics Inc For: 23 July By Investing.com - Investing.com Canada
Serina Therapeutics director Simon Farrell files initial beneficial ownership statement - Bitget
Director Simon Farrell awarded 30,500 options at Serina (SER) - Stock Titan
Serina Therapeutics, Inc. (SER) director Simon Farrell files Form 3 - Stock Titan
Serina Therapeutics Amends CEO Employment and Compensation Terms - TipRanks
Serina names Steve Ledger in amended CEO employment agreement - TradingView
Serina’s Parkinson’s trial doses all 8 first-cohort patients - Stock Titan
Serina Completes Enrollment, Dosing in First Cohort of Phase 1b Trial in Parkinson's Disease - Yahoo Finance
Serina Therapeutics Appoints Farrell Simon To Its Board Of Directors - TradingView
Serina Therapeutics Adds Industry Veteran to Board - TipRanks
Serina Therapeutics appoints Farrell Simon to Board, joins Audit and Compensation Committees - TradingView
Serina Therapeutics Appoints Farrell Simon to its Board of Directors - GlobeNewswire
Form 13D/A SERINA THERAPEUTICS For: 22 July By Investing.com - Investing.com Nigeria
Juvenescence group reports 27.3% Serina Therapeutics (SER) beneficial stake - Stock Titan
Serina Therapeutics appoints Dr. Farrell Simon to its Board - scanx.trade
Serina Therapeutics Inc. (SER) Q1 2026 Earnings: Wider-than-Expected Loss as Stock Rises 7.58%Financial Data - dars.gov.et
Serina Therapeutics (SER) Q1 2026 Earnings: EPS Miss Exceeds 30% as Clinical-Stage Firm Ramps R&D SpendGuidance Upgrade Report - dars.gov.et
SER Q1 2026 Earnings: Wider-Than-Expected Loss as Biotech Pipeline AdvancesEarnings Growth Forecast - po-news-eg.net
Serina Therapeutics Inc. (SER) Q1 2026 Earnings: Wider-Than-Expected Loss Pressures SharesMid-Term Outlook - dars.gov.et
Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease - Taiwan News
Serina Therapeutics director Brannan buys $2,029 in stock - Investing.com UK
Insider Buying: Stephen Brannan Acquires Shares of Serina Therap - GuruFocus
Serina Therapeutics director Brannan buys $2,029 in stock By Investing.com - Investing.com South Africa
Serina Therapeutics, Inc. Completes Sentinel Dosing In Cohort 1 Of Phase 1b Registrational Trial Of SER-252 For Advanced Parkinson?s Disease - marketscreener.com
Form 4 Serina Therapeutics Inc For: 9 July By Investing.com - Investing.com Nigeria
Serina Says Panel Clears Dosing More Patients in Phase 1b Trial of SER-252 in Parkinson's Disease - marketscreener.com
Serina Therapeutics advances Phase 1b trial of ... - Pluang
Serina Therapeutics Announces Completion of Sentinel Dosing - GlobeNewswire
Director Stephen K. Brannan buys 1,000 Serina Therapeutics (SER) shares at $2.03 - Stock Titan
Serina Therapeutics completes sentinel dosing in SER-252 trial - scanx.trade
Enterprise value to EBIT forward of Serina Therapeutics, Inc. – AMEX:SER - TradingView
Serina Therapeutics Inc. (SER) Q1 2026 Earnings: EPS Misses Estimates as Operating Losses ContinuePreliminary Results - dars.gov.et
Serina Therapeutics (SER) Stock Forecast and Price Target 2026 $SER - MarketBeat
SER Initiated Coverage by BTIG -- Rating Set to Buy with $8.00 P - GuruFocus
Serina Therapeutics Price Target Announced at $8.00/Share by BTIG - Moomoo
BTIG Initiates Serina Therapeutics(SER.US) With Buy Rating, Announces Target Price $8 - Moomoo
BTIG initiates Serina Therapeutics stock with buy on drug delivery platform - Investing.com Canada
BTIG initiates coverage on Serina Therapeutics with Buy rating - scanx.trade
Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program - marketscreener.com
0.52%
0.07%
Kapitalisierung:
|
Volumen (24h):